who owns wegovy

Wegovy is owned and marketed by the Danish pharmaceutical company Novo Nordisk A/S.

Who “owns” Wegovy?

• Wegovy is a brand name for the drug semaglutide, developed and commercialized by Novo Nordisk.

• Novo Nordisk holds the rights to manufacture, market, and sell Wegovy globally, through its subsidiaries such as Novo Nordisk Inc. in the United States.

Corporate ownership behind Wegovy

• Novo Nordisk itself is controlled by Novo Holdings A/S, which is wholly owned by the Novo Nordisk Foundation, a large Danish industrial foundation.

• This structure means the ultimate controlling owner of the company behind Wegovy is the Novo Nordisk Foundation , via Novo Holdings’ majority of voting shares in Novo Nordisk.

Extra context: what Wegovy is

• Wegovy is a semaglutide-based medicine used for obesity and weight management, classified as a GLP‑1 receptor agonist.

• It has become one of Novo Nordisk’s most important products and a major driver of the company’s recent growth in obesity and metabolic disease treatments.

Meta description (SEO):
Wegovy, a popular weight-loss drug based on semaglutide, is owned and marketed by Danish pharmaceutical company Novo Nordisk, which is ultimately controlled by the Novo Nordisk Foundation.

Information gathered from public forums or data available on the internet and portrayed here.